长时间作用型注射剂市场

Long-Acting Injectable Drugs

出版日期: 2022年07月31日 | 出版商:

Greystone Research Associates | 英文 | 商品交期: 最快1-2个工作天内

价格

简介目录

本报告提供全球长时间作用型注射剂市场相关调查，市场概要，以及製剂技术概要，向治疗领域，及市场参与市场企业的竞争趋势等资讯。

生物分解性聚合物
PEG
PLA/PLGA
聚醚酯
长时间作用型注射剂
- 製剂技术
BEPO (MedinCell)
ChroniJect (Oakwood Laboratories/PharmaSophia)
CriticalMix (Critical Pharmaceuticals)
Depofoam (Pacira)
FluidCrystal (Camarus)
LinkeRx (Alkermes)
Medisorb (Alkermes)
Medusa (Recipharm/Avadel)
Nanocrystals (Alkermes)
Optisomes (Talon/Spectrum)
PolyActive (Octoplus)
Q-Sphera (Midatech Pharma)
SABER/SAIB (DURECT)
SynBiosys (Innocore)
TransCon (Ascendis)

物理的流程管理方法

长时间作用型注射剂- 开发要素

配合要素
稳定
管理要素

长时间作用型产品的分析

治疗部门分析

中毒
血糖控制
感染疾病
肝炎
神经学
思觉失调症
躁郁症
肿瘤
疼痛管理
生殖医疗
不孕
子宫内膜异位症

企业简介

简介目录

Product Code: LAJD777K

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with less-frequent dosing.

What You Will Learn:

What are the marketed long-acting injectable drug products, what long-acting formulation technologies are used, and who markets them?

What are the major factors driving long-acting injectable drug demand?

What long-acting injectable drug candidates are in late-stage clinical development and what is their potential impact?

How important are drug developer-formulation technologist relationships in the long-acting market segment, and what are the key alliances in the industry?

What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for long-acting injectable drug products?

In what therapeutic market segments do long-acting injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?